Canada markets closed
  • S&P/TSX

    20,329.73
    -36.12 (-0.18%)
     
  • S&P 500

    4,402.66
    -20.49 (-0.46%)
     
  • DOW

    34,792.67
    -323.73 (-0.92%)
     
  • CAD/USD

    0.7973
    -0.0007 (-0.09%)
     
  • CRUDE OIL

    68.01
    -0.14 (-0.21%)
     
  • BTC-CAD

    50,073.64
    +1,548.26 (+3.19%)
     
  • CMC Crypto 200

    977.06
    +50.30 (+5.43%)
     
  • GOLD FUTURES

    1,809.60
    -0.90 (-0.05%)
     
  • RUSSELL 2000

    2,196.32
    -27.26 (-1.23%)
     
  • 10-Yr Bond

    1.1840
    +0.0080 (+0.68%)
     
  • NASDAQ futures

    15,080.00
    +6.50 (+0.04%)
     
  • VOLATILITY

    17.97
    -0.07 (-0.39%)
     
  • FTSE

    7,123.86
    +18.14 (+0.26%)
     
  • NIKKEI 225

    27,584.08
    -57.75 (-0.21%)
     
  • CAD/EUR

    0.6732
    +0.0010 (+0.15%)
     

Oracle, La-Z-Boy fall; General Motors, Rambus rise

·1 min read

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Wednesday:

Oracle Corp., down $4.56 to $77.08.

Investors were disappointed by the software maker's first-quarter profit forecast.

La-Z-Boy Inc., down $4.94 to $37.34.

The furniture company warned investors that supply chain problems and higher materials prices could hurt profit margins.

General Motors Co., up 95 cents to $61.76.

The auto maker will raise its spending on electric and autonomous vehicles and add two U.S. battery factories.

Carnival Corp., up 67 cents to $29.28.

The cruise operator's Cunard line gave investors an encouraging update on its plan to resume operations.

Elanco Animal Health Inc., up $1.17 to $35.98.

The animal health company is buying Kindred Biosciences for about $440 million.

Rambus Inc., up $1.67 to $21.94.

The memory chip designer is buying back $100 million of its stock and purchasing digital technology company PLDA.

Magnachip Semiconductor Corp., down $1.58 to 24.07.

The chip products maker received an order from the U.S. government to halt its sale to Wise Road Capital, pending a review.

Regeneron Pharmaceuticals Inc., down $3.91 to $523.58.

The biotechnology company slipped, despite encouraging results from a study of its COVID-19 treatment.

The Associated Press

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting